Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SNN

STRONG BUY

Smith & Nephew plc · Healthcare · United Kingdom · $12.9B · Avg Vol: $48M/d

81
StockRank
Get insider-trade alerts
Q
71
V
39
M
65
P/E (TTM)
21.4x
ROE
11.8%
D/E
0.6x
Dividend %
1.3%
Loading 1Y...
PRICE (1Y)+1.8%
28.7329.4030.0730.7431.41Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$31.12
RSI (14)
53.8
52W High
$37.90
From 52W High
0.8%

SCORE BREAKDOWN

Quality
71
ROIC
10.8%76.2
ROE
11.8%76.7
GP/Assets
40.2%80.7
Op. Margin
14.0%74.1
FCF/Assets
8.1%81.2
Piotroski
497.4
Int. Cover
5.4x52.6
D/E Ratio
0.63x25.5
Current Ratio
2.57x48.1
Value
39
P/E (TTM)
21.4x55.0
EV/EBITDA
50.7x10.8
P/FCF
15.1x70.3
P/B
12.3x9.3
P/S
2.1x66.7
Div Yield
1.3%33.1
Momentum
65
52W High %
82%74.2
RS 6M
-12%57.3
SMA 50/200
0.93x48.5
EPS Rev 4W
N/A
EPS Rev 12W
N/A
EPS Improve
+60%59.8
Q Growth
68%80.6

FUNDAMENTALS

Market Cap
$12.9B
P/E (Forward)
13.4x
Gross Margin
68.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNN are excluded.

TickerCompanyMkt CapStockRankSignal
SNNSmith & Nephew plc(you)$12.9B81STRONG BUY
LIVNLivaNova PLC$4.3B80BUY
NIOX.LNIOX Group Plc$319M87STRONG BUY
EKF.LEKF Diagnostics Holdings plc$153M79BUY
KNSAKiniksa Pharmaceuticals International, plc$4.8B87STRONG BUY
HLN.LHaleon plc$40.5B85STRONG BUY
HIK.LHikma Pharmaceuticals PLC$4.3B89STRONG BUY
CTEC.LConvatec Group PLC$5.5B65BUY
IHC.LInspiration Healthcare Group plc$27M69BUY
SPI.LSpire Healthcare Group plc$1.1B82STRONG BUY

Peer medians: ROE -5.1% · P/E 24.9x · Gross margin 54.7%

Smith & Nephew plc (SNN) — Stock Score Summary

Smith & Nephew plc (SNN) has a MoatMap StockRank of 81/100 based on Quality (71/100), Value (39/100), and Momentum (65/100) factor scores. The current signal is STRONG BUY.

Key Financial Metrics

Price$31.12
Market Cap$12.9B
P/E (TTM)21.38
P/E (Forward)13.39
Price/Book12.27
Return on Equity11.8%
Return on Invested Capital10.8%
Debt/Equity0.63x
Gross Margin68.3%
Operating Margin14.0%
Revenue Growth7.4%
Dividend Yield1.3%
Free Cash Flow$852M

Smith & Nephew plc operates in the Medical Devices industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Smith & Nephew plc’s (SNN) StockRank?
MoatMap’s StockRank for Smith & Nephew plc (SNN) is 81/100, with a Strong Buy signal. It is a composite of Quality (71), Value (39), and Momentum (65) factor ranks across MoatMap’s 20,000+ stock universe.
Does Smith & Nephew plc have an economic moat?
Smith & Nephew plc (SNN) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Smith & Nephew plc a buy, hold, or sell?
MoatMap’s current signal for Smith & Nephew plc (SNN) is Strong Buy, based on a StockRank of 81/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Smith & Nephew plc in?
Smith & Nephew plc (SNN) operates in the Healthcare sector, specifically the Medical Devices industry (United Kingdom).